Prihlásiť sa Zaregistrujte sa zadarmo

Zisková marža spoločnosti SinoMab BioScience

Aká je hodnota metriky Zisková marža spoločnosti SinoMab BioScience?

Hodnota metriky Zisková marža spoločnosti SinoMab BioScience Limited je -5,537.81%

Aká je definícia metriky Zisková marža?



Zisková marža (Profit margin) je percento čistého zisku z celkových tržieb.

Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.

Zisková marža spoločností v sektore Health Care sektor na HKSE v porovnaní so spoločnosťou SinoMab BioScience

Čomu sa venuje spoločnosť SinoMab BioScience?

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Firmy s metrikou zisková marža podobnou spoločnosti SinoMab BioScience



  • Hodnota metriky Zisková marža spoločnosti Touchpoint je -5,708.79%
  • Hodnota metriky Zisková marža spoločnosti Real Luck je -5,700.00%
  • Hodnota metriky Zisková marža spoločnosti Malachite Resources je -5,693.33%
  • Hodnota metriky Zisková marža spoločnosti Ardea Resources je -5,653.33%
  • Hodnota metriky Zisková marža spoločnosti King Island Scheelite je -5,594.26%
  • Hodnota metriky Zisková marža spoločnosti Vango Mining je -5,538.46%
  • Hodnota metriky Zisková marža spoločnosti SinoMab BioScience je -5,537.81%
  • Hodnota metriky Zisková marža spoločnosti RAPT Therapeutics je -5,490.37%
  • Hodnota metriky Zisková marža spoločnosti Graphene Manufacturing je -5,482.35%
  • Hodnota metriky Zisková marža spoločnosti Energous je -5,474.06%
  • Hodnota metriky Zisková marža spoločnosti Tanga Resources je -5,428.57%
  • Hodnota metriky Zisková marža spoločnosti Zonetail je -5,421.05%
  • Hodnota metriky Zisková marža spoločnosti Kopore Metals je -5,391.30%